Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

CD10 expression in diffuse large B-cell lymphomas does not influence survival

Abstract

CD10 expression is considered as a marker of centrofollicular-derived diffuse large B-cell lymphomas (DLBCL). The aim of our study was to determine retrospectively among 98 patients with DLBCL, enrolled in the LNH93 trial of the Groupe d’Etude des Lymphomes de l’Adulte (GELA) and homogeneously treated with high-dose cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP)], the expression of CD10 using immunohistochemistry and its correlation with morphological features and clinical parameters. Of the 98 patients studied, 33 (34%) expressed CD10. There was no correlation among clinical parameters, International Prognostic Index risk groups and CD10 expression, with the exception of lactic dehydrogenase levels, which were lower in CD10-negative cases (P=0.005). There was no significant correlation between CD10 expression and morphological subtyping of DLBCL. Indeed, centrofollicular-derived DLBCL may present with numerous immunoblasts or as an immunoblastic lymphoma. Overall survival rate and event-free survival were not significantly different according to CD10 expression (P=0.44 and P=0.34 respectively). Therefore, it appears that CD10 expression does not influence survival or event-free survival in DLBCL.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921–1925

  2. 2.

    Almasri NM, Iturraspe JA, Braylan RC (1998) CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. Arch Pathol Lab Med 122:539–544

  3. 3.

    Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, Tilly H, Coiffier B, Bosly A, Morel P, Haioun C, Gaulard P, Reyes F, Gisselbrecht C (2004) Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen. A GELA cohort study on 2837 patients. Blood 103:1222–1228

  4. 4.

    Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack A (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136–1143

  5. 5.

    Chang CC, Cleveland RP, Perkins SL (2002) CD10 expression and survival. Am J Clin Pathol 117:660–661

  6. 6.

    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244

  7. 7.

    Coiffier B (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13:325–334

  8. 8.

    Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E (2003) Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101:78–84

  9. 9.

    Dogan A, Bagdi E, Munson P, Isaacson PG (2000) CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846–852

  10. 10.

    Fang JM, Finn WG, Hussong JW, Goolsby CL, Cubbon AR, Variakojis D (1999) CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol 12:295–300

  11. 11.

    Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O’Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 90:244–251

  12. 12.

    Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin F, Hermine O, Reyes F (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472–2479

  13. 13.

    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller- Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282

  14. 14.

    Harada S, Suzuki R, Uehira K, Yatabe Y, Kagami Y, Ogura M, Suzuki H, Oyama A, Kodera Y, Ueda R, Morishima Y, Nakamura S, Seto M (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447

  15. 15.

    Hermine O, Haioun C, Lepage E, d’Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 87:265–272

  16. 16.

    Hojo H, Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Sato M, Shirakawa A, Abe M (2002) Analysis of immunoglobulin VH genes in CD10-positive diffuse large B-cell lymphoma. Pathol Int 52:586–594

  17. 17.

    Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534

  18. 18.

    Jaffee ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon

  19. 19.

    Kaplan EMP (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457

  20. 20.

    Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD (1997) Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood 90:4078–4091

  21. 21.

    Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G, Gisselbrecht C, Reyes F, Gaulard P (2002) p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13:1108–1115

  22. 22.

    McCluggage WG, Catherwood M, Alexander HD, McBride HA, Smith ME, Morris TC (2002) Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma. Histopathology 41:414–420

  23. 23.

    Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S, Suzumiya J, Podack ER, Kikuchi M (2001) CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 39:156–162

  24. 24.

    Ree HJ, Yang WI, Kim CW, Huh J, Lee SS, Cho EY, Ko YH, Charney D (2001) Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Hum Pathol 32:954–962

  25. 25.

    Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947

  26. 26.

    Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin’s lymphoma. Blood 102:4284–4289

  27. 27.

    Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG (2001) The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol 115:582–588

  28. 28.

    Xu Y, McKenna RW, Molberg KH, Kroft SH (2001) Clinicopathologic analysis of CD10+ and CD10− diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 116:183–190

  29. 29.

    Xu Y, McKenna RW, Kroft SH (2002) Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas. Mod Pathol 15:413–419

Download references

Acknowledgements

We thank Nicolas Nio, who performed the statistical analysis, Pauline Brice, Karen Leroy-Viard and Gilles Salles for critical review of the manuscript and Chafika Copeaux for technical help. Acknowledgements of source of support: this study was supported by grants from the Ministère de la Santé (PHRC AOM 95061), and from Amgen-Roche, Neuilly sur Seine, France.

Author information

Correspondence to Thierry J. Molina.

Appendix

Appendix

The following investigators participated in the study: N. Albin, C. Allard, M. Aoudjane, D. Assouline, M. Attal, B. Audhuy, M.Azagury, J.C. Barats, C. Beaumont, E. Baumelou, P. Biron, M. Blanc, D. Bordessoule, A. Bosly, K. Bouabdallah, C. Bouleuc, P. Bourquard, P. Bourquelot, F. Boué, O. Boulat, P. Brice, J. Brière, G. Brun, D. Caillot, O. Casasnovas, P. Carde, S. Castaigne, S. Chèze, B. Christian, B. Coiffier, P. Colin, C. Collet, T. Conroy, T. Cosnard, B. Corront, H. Curé, V. Delwail, L. Detourmignies, A. Devidas, H. Dombret, J.F. Dor, C. Doyen, F. Dreyfus, S. Dront, G. Dupont, B. Dupriez, J.C. Eisenmann, M. Fabbro, C. Fermé, G. Fillet, M. Flesch, C. Fruchart, J. Gabarre, C. Haioun, R. Herbrecht, O. Hermine, A. Huyn, F. Huguet, M. Janvier, E. Jourdan, J.M. Karsenti, Y. Kerneis, F. Kohser, V. Leblond, P. Lederlin, S. Lefort, P. Lenain, G. Lepeu, S. Lepretre, X. Levaltier, A. Le Rol, G. Marit, C. Martin, F. Mayer, C. Nouvel, P.Morel, M. Moriceau, J.N. Munck, G. Nedellec, F. Offner, J.M. Pavlovitch, I. Plantier, P.Y. Péaud, A.M. Peny, J. Pico, C. Platini, J.P. Pollet, B. Quesnel, O. Reman, B. Richard, R. Riou, P. Rodon, B. Salles, G. Salles, C. Sarazin, D. Schlaifer, C. Sebban, M. Simon, P. Solal-Céligny, J.J. Sotto, A. Stamatoullas, C. Soussain, G. Tertian, A. Thyss, H. Tilly, J.D. Tigaud, G. Tobelem, P. Travade, A. Van Hoof, B. Varet, A. Zaniboni and J.M. Zini.

The following pathologists actively participated to the trial and provided the slides: R. Angonin, I. Abd Alsamad, A. C. Baglin, F. Berger, N. Brousse, J.-P. Brouland, P. Brousset, D. Canioni, O. Casiraghi, D. Cazals-Hatem, A. M. Chesneau, F. Charlotte, M.-P. Chenard-Neu, C. Copie-Bergman, M.-C. Copin, M. Delos, C. Duval, G. Delsol, J. Diebold, C. Fromentin, F. Galateau, B. Gasser, B. Gosselin, C. Guettier, J. Hamels, N. Horschowski, R. Jeandel, J. P. Knopf, E. Labouyrie, C. Legendre, A. Letourneau, A. de Mascarel, V. Meignin, M. Parrens, B. Petit, M. Raphael, M. C. Raymond-Gelle, P. Straub, Y. Theate, S. Thiebaut, M. Tulliez and L. Xerri.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fabiani, B., Delmer, A., Lepage, E. et al. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch 445, 545–551 (2004). https://doi.org/10.1007/s00428-004-1129-7

Download citation

Keywords

  • Lymphoma
  • Tumor marker
  • Clinical pathology